The environment committee, led by rapporteur Françoise Grossetête, was voting on an amended version of a draft report prepared by the European Commission in September 2014. The draft proposed a total overhaul of the existing rules on medicinal products for veterinary use in the EU.

The report was adopted by 60 votes to two votes. All the members of the European Parliament will vote on whether to formally adopt the proposals in a plenary vote in May. However, given the strong support for the report among the environment committee on Wednesday, it is likely the proposals will be adopted.

One of the issues addressed by the report is a clear definition of the conditions under which veterinary medicine professionals are permitted to prescribe and sell antibiotics. To this end the report favours a ban on sales of antibiotics and all prescription-only veterinary products online.

ADVERTISEMENT

The report also calls for a list of critical antibiotics to be reserved exclusively for human consumption, provided the list is based on solid scientific criteria.

AMR

It also looks at tackling increasing antimicrobial resistance (AMR) in animals and to this end proposes banning the prophylactic use of antibiotics (use of antibiotics to prevent infection complications).

Back in September 2014, when it published its draft report, the European Commission identified the spread of AMR as "a major threat to public and animal health". In April 2015 the World Health Organisation called AMR "an increasingly serious threat to global public health that requires action across all government sectors and society".

And more recently, in December 2015, the Review on Antimicrobial Resistance, commissioned by the British government, published a paper warning against the overuse of antibiotics in farming.

Antimicrobials include anti-bacterials/antibiotics, antivirals, anti-fungals and antiprotozoals.

Data protection periods

The report also recommends implementing an 18-year data protection period for antibiotics and extending the initial marketing authorisation to the major species to two extra years.

Moreover, it suggests putting in place a five-year protection period (which cannot be combined with other periods) for certain new studies or tests carried out after authorisation has been issued, in an effort to encourage developments on or improvements to existing products, both originator and generic.

The report also proposes a system which requires regular drug safety reports for the product’s first few years of life and risk analysis and signal detection after this period.

Read more

New Department webpage to tackle the issue of antimicrobial resistance

.